Hutchmed (China) Limited (HCM) ORD USD0.10
1.00p
(0.42%)
- Add to watchlist
- Create an alert
- This stock can be held in a
1.00p
(0.42%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
1.00p
(0.42%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
229.00p
237.00p
353.00p
£2.03 bn
238.00p
228.00p
190.40p
24.79
2.00p (0.85%) Previous:
2.00p
232,950
n/a
1,000
Performance
| 1 week 1W | 4.05% | 1 year 1Y | 12.87% |
|---|---|---|---|
| 1 month 1M | 16.55% | 2 years 2Y | 7.24% |
| 3 months 3M | 10.57% | 3 years 3Y | 53.53% |
| 6 months 6M | 15.36% | 5 years 5Y | 35.6% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
| Year ending: | 31/12/2023 | 31/12/2022 |
|---|---|---|
| Revenue ($m) | 838.00 | 426.41 |
| Profit before tax ($m) | 58.31 | (410.42) |
| Adjusted EPS (¢): | 12.00 | (43.00) |
| P/E ratio | 29.60 | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Hutchmed to receive $10m milestone payment from partner Takeda
13 December 2024 09:36
-
Hutchmed lung cancer therapy gets breakthrough designation in China
12 December 2024 11:27
-
Hutchmed endometrial cancer treatment gets conditional approval in China
3 December 2024 10:14
-
HUTCHMED to Receive Milestone Payment from Takeda
13 December 2024 07:00
-
Breakthrough Therapy Designation in China
12 December 2024 07:00
-
HUTCHMED and Innovent Announce ELUNATE Approval
3 December 2024 10:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.